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Expanding the repertoire of glucocorticoid receptor target
genes by engineering genomic response elements
Verena Thormann, Laura V Glaser , Maika C Rothkegel, Marina Borschiwer, Melissa Bothe, Alisa Fuchs ,
Sebastiaan H Meijsing
The glucocorticoid receptor (GR), a hormone-activated tran-
scription factor, binds to a myriad of genomic binding sites yet
seems to regulate amuch smaller number of genes. Genome-wide
analysis of GR binding and gene regulation has shown that the
likelihood of GR-dependent regulation increases with decreased
distance of its binding to the transcriptional start site of a gene.
To test if we can adopt this knowledge to expand the repertoire
of GR target genes, we used CRISPR/Cas-mediated homology-
directed repair to add a single GR-binding site directly up-
stream of the transcriptional start site of each of four genes. To
our surprise, we found that the addition of a single GR-binding
site can be enough to convert a gene into a GR target. The gain of
GR-dependent regulation was observed for two of four genes
analyzed and coincided with acquired GR binding at the in-
troduced binding site. However, the gene-speciﬁc gain of
GR-dependent regulation could not be explained by obvious
differences in chromatin accessibility between converted genes
and their non-converted counterparts. Furthermore, by intro-
ducing GR-binding sequences with different nucleotide compo-
sitions, we show that activation can be facilitated by distinct
sequences without obvious differences in activity between the
GR-binding sequence variants we tested. The approach to use
genome engineering to build genomic response elements facil-
itates the generation of cell lines with tailored repertoires of
GR-responsive genes and a framework to test and reﬁne our
understanding of the cis-regulatory logic of gene regulation by
testing if engineered response elements behave as predicted.
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Introduction
Cis-regulatory elements embedded in the genome encode the
information to relay environmental and developmental cues into
speciﬁc patterns of gene expression. The information is decoded by
transcription factors (TFs), which bind to cis-regulatory elements
and set in motion a cascade of events to change the expression
level of genes. Typically, cis-regulatory elements harbor clusters of
binding sites for several different TFs, and the combinatorial nature
of the response element allows different outcomes depending on
which combination of TFs is active in a given cell type or under given
environmental conditions (reviewed in reference 1). Divergence in
gene regulation may also play a role in adaptation and speciation
(2) and can be driven by the loss or gain of TF-binding sites that can
occur rapidly over evolutionary time (3).
Ligand-activated TFs, such as the glucocorticoid receptor (GR),
represent an attractive model TF to study the link between TF
binding and gene regulation. An appealing feature of GR to study
gene regulation is that its activity can be turned on or off by the
addition or removal of its ligand (e.g., dexamethasone, a synthetic
glucocorticoid ligand). This on/off switch facilitates the relatively
straightforward identiﬁcation of target genes by comparing gene
expression levels between untreated cells and cells treated with
hormone. Studies with GR have shown that the genes regulated by
GR differ considerably between cell types (4, 5). Accordingly, the
genomic loci bound by GR show little overlap between different cell
types (4, 6, 7). Furthermore, cross-talk with NFκB signaling can alter
the repertoire of genomic loci bound and of the genes regulated by
GR (8, 9). The sequence composition of cis-regulatory elements
also plays a role in ﬁne-tuning the expression level of individual
genes. For instance, GR binds as a dimer to typically imperfect half
sites separated by a 3-bp spacer, and the exact sequence of the half
site, the spacer, and of the nucleotides ﬂanking the GR-binding
sequence (GBS) can modulate GR’s activity towards target genes
(10, 11).
GR can bind to tens of thousands of genomic binding sites, yet
seems to regulate a smaller number of genes (4, 7, 12, 13). Part of the
discrepancy between GR binding and gene regulation might be
technical, for example, because of false positives in ChIP-seq peak
calling and false negatives when the criteria for calling genes
regulated are too stringent. Furthermore, gene regulation is typi-
cally only sampled at a few time points and relies on the analysis of
steady-state RNA, which can yield false positives and false nega-
tives, for example, when changes in transcription rates are masked
by changes in RNA stability. The discrepancy between GR binding
and gene regulation might also be due to GR’s inability to activate
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gene expression for a subset of occupied sites (14) and could reﬂect
the inability of distal GR-binding sites to contribute to gene reg-
ulation because they lack the physical proximity to the promoter of
a gene. Accordingly, the link between GR binding and gene regu-
lation is especially weak for ChIP-seq peaks located at large dis-
tances from the promoter of genes except when the three
dimensional organization of the genome brings these distal GR
ChIP-seq peak proximal to the promoter of a gene (13). Nonetheless,
even when taking three-dimensional genome organization into
account, GR binding is a poor predictor of GR-dependent gene
regulation with only a subset of binding events (<25%) resulting the
in the regulation of associated genes (13). Recent advances in
genome editing now offer opportunities to assay the contribution
of endogenous TF-bound regions to gene regulation. For example,
by perturbing TF-bound regions in their endogenous genomic
context, their contribution to gene regulation can be assessed (15).
Similarly, catalytically inactive Cas9 fused to repressor domains,
for example, Krüppel-associated box, can be targeted to candidate
cis-regulatory elements to assess their regulatory function in the
genomic context (15, 16). Finally, a ﬁne-grained dissection of the
interplay of TF-binding sites within cis-regulatory elements can
uncover operating principles of active regulatory elements, for
example, that a cluster of GR-binding sites is required for the
activity of an individual enhancer located near the GR target gene
GILZ (13). A complementary, largely unexplored, way to study TF-
binding sites is to use genome editing combined with homology-
directed repair (HDR) to build functional response elements. By
building synthetic cis-regulatory elements, the minimal sequence
requirements for a functional response element and their ability to
recapitulate existing expression patterns can be researched.
As described above, genome-wide approaches and perturbation
of endogenous response elements can be used to identify oper-
ating principles of functional GR-binding sites. One approach to
test the validity of these ﬁndings is to determine if we can “en-
gineer” cis-regulatory elements based on these principles in the
genomic context. One of the principles we identiﬁed is that the
likelihood of GR-dependent regulation increases with decreased
distance of its binding site to the transcriptional start site (TSS) of a
gene (13). To test if adding a single GR-binding site is sufﬁcient to
convert genes into GR targets, we used HDR-mediated genome
editing to generate cell lines with a single GBS immediately up-
stream of their TSS. In addition, we compared GBS variants to test if
the sequence identity of the binding site inﬂuences GR-dependent
gene regulation. Together, our studies reveal that addition of a
single GBS can be sufﬁcient to convert genes into GR targets without
obvious differences in the level of activation between GBS variants.
Results
Addition of a single promoter-proximal GBS can render a gene
GR-responsive
To study what is required to convert endogenous genes into GR
targets, we ﬁrst set out to add a single GBS near the TSS of four
candidate genes using CRISPR/Cas9 and HDR templates (Fig 1A). To
increase our chances of observing GR-dependent regulation, we
picked a GBS variant (CGT, a synthetic sequence matching the
consensus motif), which showed the highest GR-dependent acti-
vation in previous studies (10, 11). The candidate genes were se-
lected based on the following criteria. First, we chose genes that are
not regulated by GR and display low basal levels of expression (Fig
1). This was motivated by studies showing that ectopic activation
using CRISPRa (CRISPR activation) works best for genes with low
expression levels (17, 18). Second, to increase our chances of
obtaining correctly edited clones with a TSS-proximal GBS, we only
considered genes with a possible guide RNA located ≤50-bp up-
stream of its TSS, given that HDR efﬁciency decreases with in-
creased distance between the cut site and the mutation (19). We
chose to place the GBS close to the TSS because proximal GR-
bound regions are more likely to inﬂuence the expression of nearby
genes than their distal counterparts (13). Third, we selected guide
RNAs with high computationally predicted speciﬁcity and low off-
target scores (20) and prioritized genes for which a low number of
nucleotide exchanges were needed to introduce a GBS. Finally, to
increase HDR efﬁciency, we chose candidates for which in-
troduction of the GBS resulted in PAM-blocking or guide-blocking
mutations (19).
Using this approach, we selected single-cell–derived clonal lines
for which one allele harbored the engineered GBS ≤ 50-bp up-
stream of the TSS of four genes (GYPC, IL1B, IL1R2, and VSIG1, Figs 1F
and S1) in U2OS cells stably expressing GR (U2OS-GR, (21)). As ex-
pected, basal expression levels in the absence of hormone were
unaffected by the introduced GBS for each of the genes analyzed
(Fig 2). Next, we tested if the addition of a single GBS was sufﬁcient
to convert the nearby gene into a GR target and observed a robust
increase in transcript levels for both the IL1B and IL1R2 genes upon
treatment with the synthetic glucocorticoid dexamethasone (Fig 2B
and C). The activation of the IL1B and IL1R2 genes was observed for
each of multiple independent clonal lines with an added GBS that
we tested (Fig 2B and C). Furthermore, no activation was observed
for parental U2OS-GR cells or for unedited clonal controls (Fig 2B
and C) showing that the observed activation is a consequence of
the GBS addition. For the other two genes we edited (GYPC and
VSIG1), the GBS addition did not convert the gene into a GR target
(Fig 2A and D). Together, these experiments show that the addition
of a single GBS near the TSS of a gene can be sufﬁcient to convert it
into a GR target.
Gene-speciﬁc GR binding partially explains the gene-speciﬁc
acquirement of GR-dependent regulation upon GBS addition
To test if locus-speciﬁc GR binding could explain the gene-speciﬁc
acquired activation, we analyzed GR binding at the added GBSs by
chromatin immunoprecipitation (ChIP). Consistent with the ac-
quired GR-dependent activation, we found that GR was recruited to
the IL1R2 and IL1B loci upon hormone treatment for clonal lines
with an added GBS, whereas no binding was observed for unedited
control cells (Fig 2F and G). For the GYPC gene, the ChIP-seq data for
the parental U2OS-GR shows a small peak immediately upstream of
its TSS (Fig 1B). Accordingly, we ﬁnd a modest hormone-dependent
recruitment of GR to the TSS of GYPC for unedited cells, which was
slightly higher for the clonal line with an added GBS (Fig 2E). For the
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Figure 1. Genes selected for genomic GBS integration at the respective promoter region.
(A) Overview of the experimental design of our study. (B–E) Tracks showing H3K27ac and GR ChIP-seq normalized tag density, ATAC-seq, and RNA-seq reads for
U2OS-GR cells (the non-edited parental cell line) that were treated as indicated. Genomic regions surrounding the loci of GBS integration are shown for GYPC (B), IL1B (C),
IL1R2 (D), and VSIG1 (E). The genomic site targeted for GBS integration is highlighted in blue and its distance in base pairs to the TSS is indicated. (F) HDR-mediated
genome editing to introduce the CGT GBS upstream of the IL1R2 gene. The sequence of the gRNA, the sequence of the introduced GBS, and the efﬁciency of
successfully edited single-cell–derived clonal lines are shown on the left. Sanger sequencing for a successfully edited clone and the sequence for each allele are shown
on the right.
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VSIG1 gene, no GR recruitment was observed regardless of whether
a GBS was added or not (Fig 2H). Importantly, for all clonal lines
analyzed, we observed robust hormone-dependent GR binding at
the endogenous GILZ locus, which served as a positive control (pos.
ctrl) and shows that the ChIP efﬁciency was comparable between
our clonal lines (Fig 2E–H).
Given GR’s preference for binding at accessible chromatin (7),
differences in accessibility could explain the locus-speciﬁc binding
of GR to the added GBS. To test this hypothesis, we generated ATAC-
seq (assay for transposase-accessible chromatin, (22)) data for
parental U2OS-GR cells both in the presence and absence of
dexamethasone. Visual inspection of the ATAC-seq data revealed a
similar, relatively low, ATAC-seq signal (Fig 1B–E) for each of the loci
examined. This indicates that the regions where we added the GBS
are relatively inaccessible and that the gene-speciﬁc binding does
not appear to be a consequence of marked differences in chro-
matin accessibility between regions. Similarly, H3K27ac levels, a
marker of active enhancers, were similarly low in untreated cells for
each of the genes analyzed (Fig 1B–E).
To test if activation by another transcriptional activator shows
the same gene-speciﬁc activation pattern as GR, we targeted dCas9-
SAM (17) to the TSS of each of the four candidate genes. The dCas9-
SAM system is a powerful tool to activate genes upon TSS-proximal
recruitment and consists of a nucleolytically dead Cas9 protein
fused to the VP64 activation domain. In addition, the system uses a
modiﬁed guide RNA containing two MS2 stem loops that recruit
MS2-p65-HSF1 fusion proteins to further boost activation. Targeting
of dCas9-SAM to the TSS of the IL1R2 and IL1B genes resulted in a
robust activation (>100-fold increase over control non-targeting
guide RNA, Fig 3). In contrast, targeting dCas9-SAM to the TSS of
genes that did not acquire GR-dependent activation upon GBS
addition resulted in marginal activation (2.9-fold) for VSIG1,
whereas the GYPC gene was not activated by dCas9-SAM (Fig 3).
Together, our results show a similar pattern of activation by GR
and by targeting the dCas9-SAM system that cannot be explained by
obvious differences in chromatin accessibility based on ATAC-seq
data. For GR, this gene-speciﬁc activation can be partially explained
by gene-speciﬁc GR recruitment. Speciﬁcally, the most robust GR
recruitment was observed for the two genes that acquired GR-
dependent regulation upon GBS addition, whereas no binding was
detected for VSIG1, which could not be converted into a GR target.
Activation of the endogenous IL1R2 gene by GBS variants
GR is known to bind directly to a broad spectrum of sequences that
differ in their precise sequence composition (23). In addition to
recruiting GR to deﬁned genomic loci, the sequence of the binding
site can also modulate the activity of GR downstream of binding (10,
11, 23). To test if GBS variants, other than the CGT variant we initially
tested, can accommodate GR-dependent regulation of the IL1R2
Figure 2. Genomic insertion of a single GBS results in gene-speciﬁc acquired GR binding and GR-dependent transcriptional regulation.
(A–D) Relative mRNA expression levels as determined by qPCR for (A) GYPC (only one single-cell–derived clonal line was analyzed: n = 1) (B) IL1B (n = 4), (C) IL1R2 (n = 3),
and (D) VSIG1 (n = 3) are shown for unedited parental U2OS-GR cells (wt), for unedited clonal control cell lines, and for clonal cell lines with an integrated GBS at
the target gene as indicated. Averages ± SEM for cell lines treated overnight with 1 μMdexamethasone (dex) or with ethanol (−) as vehicle control are shown. Dots show the
values for each individual clonal line. Statistical tests were performed using an unpaired one-sided Mann–Whitney U test comparing each dex-treated group with
its untreated counterpart. (E–H) GR occupancy at the edited genes was analyzed by ChIP followed by qPCR for cells as indicated treated with vehicle control (−) or 1 μM dex
for 90 min. (E–H) Average percentage of input precipitated ± SEM from three independent experiments is shown for an unedited clonal control cell line and for a
clonal cell line edited at either the (E) GYPC, (F) IL1B, (G) IL1R2, or (H) VSIG1 locus. Left panel shows binding at the edited promoter. Right panel binding at the unedited GILZ
locus, which serves as control for comparable ChIP efﬁciencies between clonal lines. Statistical tests were performed using an unpaired one-sided Mann–Whitney U test
comparing GR binding at the IL1R2 promoter between dex-treated clonal control and the dex-treated edited clonal line as indicated.
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gene, we generated single-cell–derived clonal lines for three ad-
ditional GBS variants (Figs 4A and S2). We picked two GBS variants
PAL (a synthetic sequence with perfect palindromic half sites) and
GILZ (a GBS derived from a GR-bound region near the GILZ gene)
that showed markedly lower activities than the CGT sequence in
previous studies using reporter assays and one with comparable
activity FKBP5-2 (a GBS derived from a GR-bound region near the
FKBP5 gene) (10, 11). Next, we tested if these GBS variants could also
convert the IL1R2 gene into a GR target and found that this was the
case for each of the variants tested (Fig 4B). Accordingly, ChIP
analysis showed GR binding at the TSS of the IL1R2 gene upon the
addition of each GBS variant tested (Fig 4C).
For a quantitative comparison between the GBS variants, we
generated multiple independent clonal lines for each GBS variant
(n ≥ 3). This is important for a meaningful comparison between GBS
variants, given the high degree of variability in the level of acti-
vation observed between individual clones with the same GBS
variant (Fig 2C). However, when we averaged the level of activation
across clonal lines with the same GBS, we observed no signiﬁcant
differences between the GBS variants in the levels of IL1R2 acti-
vation (Fig 4B). As expected, this was also the case for the en-
dogenous target gene DUSP1, a GR target gene located on another
chromosome, which served as an internal control to ensure that GR
activity was comparable across clonal lines (Fig 4B). Similarly, the
kinetics of IL1R2 activation after GR activation by dexamethasone
was comparable for each of the GBS variants (Figs 4D and S3A for
the unedited control gene DUSP1). Taken together, these results
indicate that several GBS variants can convert the IL1R2 gene into a
GR target with similar levels of activation for each variant.
Comparison of engineered GBS variants at the endogenous GILZ
enhancer
We previously showed that deletion of an individual endogenous
GBS (GBS1, Fig 5A) resulted in a partial reduction (~60%) of
hormone-induced GILZ levels when compared with either parental
U2OS-GR cells or to unedited clonal controls ((13) and Fig 5B). To
test if other GBS variants can substitute for the endogenous GBS1,
we ﬁrst analyzed the activity of several variants using a luciferase
reporter (Fig 5C and D). We found that the level of activation was
comparable for different GBS variants with the exception of the PAL
sequence, a high-afﬁnity GBS variant (10), which showed a lower
level of activation (Fig 5D). Based on these ﬁndings, we decided to
use HDR to convert the endogenous GBS1 to the FKBP5-2 or to the
PAL sequence (Fig S4), the two variants with the highest and lowest
reporter activity, respectively. Next, we analyzed the effect of
changing the sequence of the endogenous GBS1 using HDR and
found that the level of activation for the PAL and FKBP5-2 variants
was markedly higher than that observed when the GBS1 was de-
leted (Fig 5B and E). In fact, the activation for both variants was
indistinguishable from the activation observed for parental U2OS-
GR cells or for unedited clonal controls (Fig 5E). This was also
observed for the unedited DUSP1 gene, which serves as a control to
make sure that GR activity is comparable among the clonal lines we
analyzed (Fig 5E). Notably, the in vitro afﬁnity of GR for the PAL
sequence is an order of magnitude higher than for the endogenous
GBS1 sequence (10). To test if the higher afﬁnity of GR for the PAL
sequence might facilitate GILZ activation at lower hormone con-
centrations, we assayed the levels of activation observed at 100 pM
and 10 nM dexamethasone. Consistent with our expectation, ac-
tivation of the GILZ gene was lower at lower hormone concentra-
tions (Fig 5F). However, when comparing GBS variants at a given
hormone concentration, we observed similar levels of activation,
indicating that the sequence identity of the GR-binding site does
not affect the dose response of the GILZ gene (Figs 5F and S5A for
the unedited control gene FKBP5). Similarly, the kinetics of acti-
vation after hormone treatment was comparable for each of the
GBS variants analyzed (Figs 5G and S5B for the unedited control
gene DUSP1). Together, these results indicate that both the PAL and
the FKBP5-2 GBS variants can substitute for the original GBS1 se-
quence at the GILZ gene without apparent differences between GBS
variants in the level of GR-dependent activation observed.
Discussion
The ultimate quest in deciphering cis-regulatory logic is to reach a
level of understanding that would allow an accurate quantitative and
Figure 3. Activation of targeted loci by the Cas9 activator dCas9-SAM.
(Top) Schematic of the dCas9 synergistic activation mediator (dCas9-SAM)
targeted to the promoter region of a gene. (Bottom) Fold induction of GYPC, IL1B,
IL1R2, and VSIG1 expression upon targeting dCas9-SAM to its TSS. The average fold
change induced by a gRNA targeted to the promoter region of the respective gene
relative to a control non-targeting gRNAs ± SEM from three independent
experiments is shown.
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qualitative prediction of gene expression levels based on regulatory
sequence composition. If identiﬁed, such knowledge would, for
example, facilitate the rational design of gene regulatory circuits to
generate cells with desired gene expression patterns. A broad range
of methods can help identify the rules that govern transcriptional
output, including perturbation experiments, genome-wide mapping
of functional elements and high-throughput reporter assays to
measure the activity of promoter and enhancer regions (24). By
building synthetic circuits, the accuracy of the elusive regulatory
code can be tested and can help identify possible gaps in our
knowledge when the predicted results are in conﬂict with the
measured transcriptional output. Here, we used genome editing to
evaluate two traits associated with GR-dependent gene regulation.
The ﬁrst trait we evaluated is the positive correlation between
GR-dependent regulation of a gene and promoter-proximal GR
binding (13). By adding a promoter-proximal GBS to several genes,
we could demonstrate that the addition of a single GR-binding site
can be sufﬁcient to convert a gene normally not regulated by GR
into a target gene. For the converted genes (IL1B and IL1R2, Fig 2), we
observed robust GR recruitment to the added GBS. In contrast,
either no recruitment or a less robust acquired recruitment of GR
was found for the genes that could not be converted (VSIG1
and GYPC, Fig 2) indicating that GR binding is required for the ac-
quired GR-dependent regulation. Interestingly, the equivalent
gene-speciﬁc ability to activate genes was found for the synthetic
dCas9-SAM activator. Because GR almost exclusively binds to re-
gions of open chromatin (7), differences in chromatin accessibility
would provide a straightforward explanation for the gene-speciﬁc
acquired activation observed. However, arguing against this ex-
planation, we did not observe obvious differences in chromatin
Figure 4. Comparison of IL1R2 activation levels by inserted GBS variants.
(A)Overview of the IL1R2 promoter region showing the location of the GBS integration, the sequence of integrated GBS variants, the GR ChIP-seq tag density for dex-treated
U2OS-GR cells and the location of a GR ChIP-seq peak that is already present at the locus before editing (IL1R2 GR wt peak). (B) Relative mRNA expression levels
as determined by qPCR for IL1R2 and for the unedited control GR target gene DUSP1 are shown for unedited parental U2OS-GR cells (wt), for unedited clonal control cell
lines, and for clonal cell lines with an integrated GBS as indicated at the IL1R2 gene. Averages ± SEM for cell lines treated overnight with 1 μM dexamethasone (dex) or
with ethanol (−) as vehicle control are shown. Dots show the values for each individual clonal line. Statistical tests were performed using an unpaired two-sided
Mann–Whitney U test comparing the RNA level for dex-treated FKBP5-2 GBS samples with the dex-treated RNA levels for each of the other GBS variants analyzed. (C) GR
occupancy was analyzed by ChIP followed by qPCR for clonal lines as indicated and treated with vehicle control (−) or 1 μM dex for 90 min. Average percentage of input
precipitated ± SEM from three independent experiments is shown for the locus where the GBS was inserted (IL1R2 promoter), the IL1R2 wt peak, a positive control
region (GILZ), and a negative control region (TAT). (D) Relative mRNA expression levels as determined by qPCR for the IL1R2 gene for unedited parental U2OS-GR cells (wt),
for unedited clonal control cell lines and for clonal cell lines with an integrated GBS as indicated at the IL1R2 gene. Averages ± SEM for cell lines treated for 4, 6, 8, or 10 h
with 1 μM dex or vehicle control (−) is shown. Dots indicate the value of each individual clonal cell line.
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Figure 5. Effect of GBS1 sequence identity on GR-dependent GILZ activation.
(A) Tracks showing H3K27ac and GR ChIP-seq tag density, ATAC-seq, and RNA-seq reads at the GILZ locus for U2OS-GR cells treated as indicated. The GILZ GBS1 targeted for
editing is highlighted in brown and the distance in kilo base pairs (kb) to the next TSS is indicated. (B) Relative GILZ mRNA expression is shown for parental
U2OS-GR cells, for unedited clonal controls, and for clonal lines with a deleted GBS1. The average ± SEM of at least ﬁve clonal cell lines treated overnight with 1 μM dex or
vehicle control (−) is shown. Dots show the values for each individual clonal line. Statistical tests were performed using an unpaired two-sided Mann–Whitney U
test comparing dex-treated GILZ levels between clonal lines with a deleted GBS1 and their unedited clonal control counterpart. (C) DNA sequence of GBS variants analyzed.
(D) Relative fold activation of luciferase reporters with GBS variants as indicated comparing cells treated with vehicle control (etoh) and cells treated overnight with
1 μM dex. Averages ± SEM from three independent experiments are shown. (E) Relative mRNA expression levels as determined by qPCR for GILZ and for the
unedited control GR target gene DUSP1 are shown for unedited parental U2OS-GR cells (wt), for unedited clonal control cell lines, and for clonal cell lines with GBS variant
as indicated at the GILZ GBS1 locus. Averages ± SEM for cell lines treated overnight with 1 μM dexamethasone (dex) or with ethanol (−) as vehicle control are
shown. Dots show the values for each individual clonal line. Statistical tests were performed using an unpaired two-sided Mann–Whitney U test comparing dex-treated
GILZ levels between clonal lines for each introduced GBS variant and their unedited clonal control counterpart. (E, F) Same as for (E) except that GILZ mRNA levels
are shown for cells treated overnight with 0.1 nM dex, 10 nM dex, or vehicle control (−). (E, G) Same as for (E) except that cells were treated for 0.5, 1, 2, or 4 h with 1 μM dex.
Engineering target genes of transcription factors Thormann et al. https://doi.org/10.26508/lsa.201800283 vol 2 | no 2 | e201800283 7 of 12
accessibility or differences in H3K27ac levels between converted
genes and genes that could not be converted into GR targets for
unedited parental U2OS-GR cells (Fig 1). However, we cannot rule
out that the GBS introduction might inﬂuence H3K27ac levels,
DNA accessibility, or other chromatin characteristics at the edited
locus, although some of our ﬁndings argue against profound
changes. First, introduction of the GBS does not inﬂuence basal
expression levels of the edited genes (Fig 2). Second, the activation
by targeted recruitment of dCas9-SAM, which wasmeasured in non-
manipulated parental cells, follows the same gene-speciﬁc pattern
of activation that was observed for GR. Finally, ChIP experiments
indicate that H3K27ac levels at the edited IL1R2 promoter locus do
not change upon addition of a GBS (Fig S3B) either in the presence
or absence of GR activation by the addition of dexamethasone. The
presence of endogenous GR-binding sites near the IL1B and IL1R2
genes (Fig 1C and D) and the absence of a GR-binding site near the
VSIG1 gene could also explain why the addition of a GBS is able to
convert only IL1B and IL1R2 into GR targets. However, the presence
of a nearby GR-binding site does not appear to be the entire ex-
planation for gene-speciﬁc acquired gene regulation, given that the
GYPC gene, which cannot be converted, also harbors GR-binding
sites near its TSS (Fig 1B). Alternative explanations for the gene-
speciﬁc acquirement of activation could be differences in DNA
methylation and that the sequence context for the IL1R2 and IL1B
encodes recognition sequences for factors that accommodate GR
binding and activation from the introduced GBS. Sequence features
that accommodate GR-dependent activation could be identiﬁed
computationally. However, this would require the editing of a larger
number of genes to ﬁnd common features among converted genes.
Alternatively, we could disrupt candidate sequences present
at converted genes to assay their role in accommodating GR-
dependent activation. Notably, the initial response element we
introduced consisted of just a single GBS sequence, which to our
surprise was sufﬁcient to convert some genes into GR targets. Likely,
activation of other genes requires more complex response ele-
ments consisting of multiple GBS’s or of a GBS and binding sites for
TFs known to synergize with GR (25). In addition, the ability of a
single GBS to convert a gene into a GR target might be cell type–
speciﬁc, something we intend to test in the future.
Profound changes in GR occupancy patterns are also observed
when GR binding is compared between mouse and human mac-
rophages (26). This divergence is accompanied by changes in the
repertoire of responsive genes between species and is associated
with gains and losses of GR recognition sequences (26). Similar to
the targeted nucleotide substitutions we introduced here, the
evolutionary turnover of GR-binding sites is predominantly driven
by nucleotide substitutions as a consequence of mutations (26).
Notably, in contrast to the promoter-proximal GBSs we added,
most of the endogenous GR binding occurs promoter-distal (4, 7, 12).
In fact, GR binding is biased against accessible chromatin located at
promoter regions, which can be partially explained by the presence
of fewer GR recognition sequences in promoter regions when
compared with their promoter-distal counterparts (4, 12). A possible
reason for this bias is that there might be selection against
promoter-proximal GR binding to safe-guard cell type–speciﬁc
transcriptional consequences of glucocorticoid signaling given that
Figure 6. Unsophisticated enhancer logic: addition
of a single occupied GBS sufﬁces to convert a
nonresponsive gene into a GR target.
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promoter-proximal GR binding is associated with gene regulation
regardless of cell type examined, whereas distal binding is more
likely to result in cell type–speciﬁc gene regulation (4).
The second trait we evaluated is the sequence of GR’s DNA-
binding site, which can inﬂuence the magnitude of transcriptional
activation by GR (10, 11, 27). By changing the sequence identity of the
introduced GR-binding site at the IL1R2 gene and of a GBS at an
endogenous GR-bound region near the GILZ gene, we found that
distinct variants facilitate equivalent levels of GR-dependent ac-
tivation. This indicates that the sequence identity of the GBS does
not direct markedly distinct levels of activation for either locus
examined. Our ﬁndings in the genomic context are in contrast to
previous studies showing that the sequence identity of the GBS can
have an impact on the magnitude of GR-dependent activation (10,
11). One possible explanation for this discrepancy is that our ap-
proach may not have the sensitivity to detect subtle differences in
activity. For example, because of the high levels of variation in the
level of activation we observe for a given GBS variant when
comparing individual clonal lines (Fig 4C). This clonal variability
precludes the identiﬁcation of signiﬁcant differences when small
numbers of clonal lines are analyzed. Another possible explanation
is that the ability of GBS variants to induced different levels of
activation is context speciﬁc. Notably, the expression of endoge-
nous GR target genes can be controlled by one or multiple GR-
bound enhancers (13, 28), which might mask GBS-speciﬁc activities.
Furthermore, studies showing GBS-speciﬁc activities (10, 27, 29)
were performed using minimal promoters (SV40 or thymidine ki-
nase), whereas we studied activation from the endogenous pro-
moters of the GILZ and IL1R2 genes, respectively. Thus, GBS-speciﬁc
levels of activation might only occur for speciﬁc types of promoters,
an idea we would like to pursue in forthcoming studies.
Taken together, our engineering of cis-regulatory elements argue
for an unsophisticated enhancer logic (30) where a single occupied
GBS can be sufﬁcient to activate genes when it is located promoter-
proximal (Fig 6). Moreover, we ﬁnd that acquired activation can be
mediated by distinct GBS variants without obvious differences in
activity between variants. To our knowledge, this is the ﬁrst study to
use genome engineering to add a binding site for a mammalian TF to
expand its repertoire of endogenous target genes. We started by
building response elements consisting of just a single GR-binding
site. By adding complexity to the response element, increasing the
distance between the response element and the promoter and by
analyzing larger numbers of genes, the engineering approach pro-
vides a framework to reﬁne our understanding of the cis-regulatory
logic of gene regulation which would ultimately facilitate the con-
struction of cells with desired gene expression proﬁles.
Materials and Methods
Cell culture, transient transfections, and luciferase assays
U2OS cells with stably integrated rat GR α (21) were cultured in
DMEM supplemented with 5% FBS at 37°C and 5% CO2. The pGILZ1
construct containing a GR-bound region near the GILZ gene driving
a luciferase reporter gene has been described previously (31). GBS1,
encoded in the pGILZ1 construct, was mutated by site-directed
mutagenesis using primers listed in Table 1. Transient trans-
fections of U2OS-GR cells were performed as described previously
(10). Luciferase activity was measured using the Dual Luciferase
Reporter Assay kit (Promega).
RNA-seq U2OS-GR cells
RNA-seq data for U2OS-GR cells was generated as previously de-
scribed (32), except that cells were treated with 1 μM dexameth-
asone for 24 h in addition to the 4-h treatment.
ATAC-seq U2OS-GR cells
For ATAC-seq, U2OS-GR cells were treated with 1 µM dexamethasone
or vehicle control (ethanol) for 90 min. ATAC-seq was performed
with 100,000 cells per treatment according to the Omni-ATAC-
seq protocol (33), with the following modiﬁcations: (1) the
transposase reaction was stopped precisely after 30 min through
the addition of 2.5 μl of 10% SDS and (2) the transposed DNA
fragments were PCR-ampliﬁed using the p5-containing primer
59–AATGATACGGCGACCACCGAGATCTACACTCGTCGGCAGCGTC-39 and
the p7-containing primer 59-CAAGCAGAAGACGGCATACGAGATGTA-
AGTCACGTCTCGTGGGCTCGG-39 or 59-CAAGCAGAAGACGGCATACGAG-
ATTTCAGTGAGGTCTCGTGGGCTCGG-39 (p7-containing primers have
different barcodes for multiplexed sequencing).
Libraries were sequenced on an Illumina HiSeq 4000 with 50-bp
paired-end reads to a sequencing depth of 50 M reads. Raw reads
were mapped to the reference assembly hg19 using Bowtie2 v.2.1.0
(–very-sensitive) (34). SAMtools (35) was used for conversion of SAM
Table 1. Primer sequences for SDM of luciferase reporter constructs and
HDR templates.
Name Sequence 59 to 39
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to BAM ﬁles and sorting. Duplicate reads were removed with Picard
tools v.2.17.0 (MarkDuplicates) (http://broadinstitute.github.io/
picard/). BigWig ﬁles were generated with bamCoverage from
deepTools (36).
ChIP and ChIP-seq
ChIP-qPCR for GR and H3K27ac (C15410196; Diagenode) was per-
formed as previously described (13) using primers listed in Tables 2
and 3. For H3K27ac ChIP-seq experiments, U2OS-GR cells were
treated for 1.5 h with 1 μM dexamethasone, cross-linked with 1%
formaldehyde for 3 min, and harvested. Chromatin was precipitated
using 1 µg of anti-H3K27ac antibody (C15410196; Diagenode). Se-
quencing libraries were prepared using the NEBNext Ultra DNA
Library Prep kit (E7370; NEB) according to the manufacturer’s in-
structions and submitted for paired-end Illumina sequencing. Data
processing: paired-end Illumina sequencing reads were mapped to
the human genome (hg19) using STAR (–alignIntronMax 1) (37) and
converted to the bigWig format for visualization.
Genome editing
The HDR templates for genome editing were generated by cloning an
~2-kb genomic region ﬂanking the targeted integration site (genomic
coordinates of cloned regions listed in Table 4) into the zero blunt
PCR cloning vector (Thermo Fisher Scientiﬁc). Sequence changes in
these templates were introduced by site-directedmutagenesis, using
the primers listed in Table 1. To avoid repeated Cas9-editing mod-
iﬁcations, the added GBSs overlapped with the gRNA target se-
quence (genomic location of introduced GBSs listed in Table 5).
gRNAs for genome editing (Table 6) were designed using the CRISPOR
webtool (http://crispor.tefor.net/) and cloned into the sgRNA/Cas9
expression construct PX459 (#62988; Addgene). To generate clonal
lines with HDR-induced sequence changes, U2OS-GR cells were
transfected using 600 ng of the gRNA construct and 3 μg of the HDR
template by nucleofection (Lonza Nucleofector kit V) according to the
manufacturer’s instructions. Subsequently, successfully transfected
cellswere selected by treating cells with puromycin (2.5μg/ml) for 24 h.
To increase gene editing by HDR, we treated transfected cells for
24 h with 10 μM SCR7 (XcessBio Biosciences). Single-cell–derived
clonal cell lines were genotyped by PCR using genomic DNA isolated
with the DNeasy Blood and Tissue kit (QIAGEN) and primers binding
outside the HDR template.
RNA preparation and analysis by quantitative real-time PCR
(qPCR)
Cells were cultured to conﬂuency and treated with dexamethasone
or vehicle control (ethanol) for the times and hormone concen-
trations as indicated in the ﬁgure legends. After the hormone
treatment, RNA was extracted, reverse-transcribed, and analyzed by
qPCR as described previously (10) using the primer pairs listed in
Table 7. For the analysis of lowly expressed genes (IL1R2, VSIG1, IL1B,
and GYPC), the cDNA was diluted 1:3.5; for all other genes 1:25.
dCas9-SAM activation of endogenous genes
To test if dCas9-SAM could activate endogenous target genes when
recruited to the sites where we added the GBSs, we created gRNAs
containing MS2 loops by cloning the target sequence (Table 6) into
the sgRNA(MS2) plasmid (#61424; Addgene). Next, U2OS-GR cells
were transfected with 600 ng each of the MS2-containing gRNA,














Table 3. Primer sequences for the quantiﬁcation of H3K27Ac in ChIP
experiments.













Table 2. Primer sequences for the quantiﬁcation of GR binding in ChIP
experiments.
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dCas9-VP64 expression construct (#48223; Addgene), and an MS2-
p65-HSF1 activator expression construct (#61423; Addgene) by
nucleofection (Lonza Nucleofector kit V) according to the manu-
facturer’s instructions. 24 h after transfection, total RNA was iso-
lated using the RNeasy kit (QIAGEN), DNase-I digested and reverse
transcribed using random primers (NEB) and analyzed by qPCR
using primers listed in Table 7. To calculate the fold up-regulation,
we ﬁrst calculated the RNA level of the targeted gene relative to
RPL19 (which served as an internal control) observed when cells
were transfected with the promoter-targeting gRNA. In addition, we
determined the RNA level of the targeted gene for each of three
guide RNAs that target the promoter of another gene. Finally, the
fold regulation by the targeting gRNA is determined by dividing
the RNA level for the targeting gRNA by the average RNA level for the
three non-targeting gRNAs.
Data access
Data to create the genome-browsed screenshots (Figs 1, 4, 5)
can be found at ArrayExpress: ChIP-seq data GR: E-MTAB-2731;
RNA-seq data for U2OS-GR cells: E-MTAB-6738 and E-MTAB-7745;
ChIP-seq data H3K27ac: E-MTAB-7747; and ATAC-seq data: E-MTAB-
7746.
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Supplementary Information is available at https://doi.org/10.26508/lsa.
201800283.
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